Chest
Volume 146, Issue 4, Supplement 2, October 2014, Page 860A
Pulmonary Vascular DiseaseEffect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study
Section snippets
Abstract
SESSION TITLE: Pulmonary Hypertension
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 28, 2014 at 02:45 PM - 04:15 PM
PURPOSE: Combining drugs that target different pathophysiological pathways is a recommended treatment strategy in PAH [1]. COMPASS-2 investigated the safety and efficacy of adding bosentan in PAH patients already receiving sildenafil.
METHODS: In this double-blind, placebo-controlled, Phase IV, add-on, event-driven study, patients with symptomatic PAH
References (0)
Cited by (0)
Copyright © 2014 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.